Explain this page
Arphra AIPlain-English read on Gilead Sciences, Inc.’s valuationTransactions
24
0 buys · 24 sells
Bought
$0
Open market
Sold
$48.31M
Open market
Net flow
−$48.31M
Buys − sells
Transactions
| Insider | Role | Action | Shares | Price | Value | Trade date | Filing |
|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 6,950 | $128.79 | $895.07K | Apr 28, 2026 | Apr 29, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 3,050 | $130.01 | $396.53K | Apr 28, 2026 | Apr 29, 2026 |
| Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $140.96 | $422.88K | Apr 15, 2026 | Apr 16, 2026 |
| Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $140.96 | $422.88K | Apr 15, 2026 | Apr 16, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $136.82 | $1.37M | Mar 27, 2026 | Mar 30, 2026 |
| Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $144.23 | $432.69K | Mar 16, 2026 | Mar 17, 2026 |
| Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $144.23 | $432.69K | Mar 16, 2026 | Mar 17, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 6,419 | $145.18 | $931.9K | Feb 27, 2026 | Mar 02, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 100 | $145.71 | $14.57K | Feb 27, 2026 | Mar 02, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 3,481 | $144.04 | $501.39K | Feb 27, 2026 | Mar 02, 2026 |
| Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 200 | $155.62 | $31.12K | Feb 17, 2026 | Feb 18, 2026 |
| Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $154.43 | $463.29K | Feb 17, 2026 | Feb 18, 2026 |
| Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 18,405 | $154.18 | $2.84M | Feb 17, 2026 | Feb 18, 2026 |
| Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 9,395 | $154.91 | $1.46M | Feb 17, 2026 | Feb 18, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $150.00 | $17.35M | Feb 05, 2026 | Feb 06, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 4,968 | $140.24 | $696.73K | Jan 28, 2026 | Jan 29, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 5,032 | $139.54 | $702.19K | Jan 28, 2026 | Jan 29, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $135.00 | $15.61M | Jan 23, 2026 | Jan 26, 2026 |
| Bluestone Jeffrey | director | Sell | 5,000 | $123.50 | $617.5K | Jan 20, 2026 | Jan 21, 2026 |
| Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $124.31 | $372.93K | Jan 15, 2026 | Jan 16, 2026 |
| Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $124.31 | $372.93K | Jan 15, 2026 | Jan 16, 2026 |
| O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $124.83 | $1.25M | Dec 29, 2025 | Dec 30, 2025 |
| Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $122.00 | $366K | Dec 15, 2025 | Dec 16, 2025 |
| Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $122.00 | $366K | Dec 15, 2025 | Dec 16, 2025 |
By insider
- O'Day Daniel Patrick−$39.71Mdirector, officer: Chairman & CEO0B · 11S
- Mercier Johanna−$5.92Mofficer: Chief Comm & Corp Aff Officer0B · 7S
- Dickinson Andrew D−$2.06Mofficer: Chief Financial Officer0B · 5S
- Bluestone Jeffrey−$617.5Kdirector0B · 1S
Beneficial ownership filings
Schedule 13D / 13G — investors holding more than 5% of GILD-US.
DB · acquisition_ownership14
| Filed | Reporting person | Form | Type | Aggregate owned | % Class | Sole voting | Shared voting | Citizenship | |
|---|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Gilead Sciences, Inc. | — | CO | — | +13.90% | 5.32M | 0 | Delaware | SEC → |
| Apr 05, 2024 | Gilead Sciences, Inc. | — | CO | — | +19.90% | 7.35M | 0 | Delaware | SEC → |
| Feb 20, 2024 | Gilead Sciences, Inc. | — | CO | — | +9.60% | 4.13M | 0 | Delaware | SEC → |
| Oct 25, 2023 | Gilead Sciences, Inc. | — | CO | — | +19.90% | 13.07M | 0 | — | SEC → |
| Oct 19, 2023 | Gilead Sciences, Inc. | — | CO | — | +6.70% | 2.93M | 0 | Delaware | SEC → |
| Feb 13, 2023 | 95-1411037 | — | IA | — | +5.50% | 68.77M | 0 | Delaware | SEC → |
| Feb 06, 2023 | Gilead Sciences, Inc. | — | CO | — | +7.30% | 3.48M | 0 | Delaware | SEC → |
| Aug 08, 2022 | Gilead Sciences, Inc. | — | CO | — | +14.80% | 13.7M | 0 | Delaware | SEC → |
| Jul 08, 2022 | (1)Names of reporting persons. BlackRock, Inc. | — | HC | — | +10.10% | 115.81M | 0 | Delaware | SEC → |
| Feb 17, 2022 | Gilead Sciences, Inc. | — | CO | — | +4.30% | 11.11M | 0 | State of Delaware | SEC → |
| Feb 11, 2022 | 95-1411037 | — | IA | — | +8.50% | 107.14M | 0 | Delaware | SEC → |
| Feb 10, 2022 | Gilead Sciences, Inc. | — | CO | — | +4.30% | 11.11M | 0 | Delaware | SEC → |
| Feb 01, 2022 | (1) BlackRock, Inc. | — | HC | — | +9.50% | 106.1M | 0 | Delaware | SEC → |
| Sep 10, 2021 | Gilead Sciences, Inc. | — | CO | — | +5.50% | 4.85M | 0 | Delaware | SEC → |
Top 10 holders · 8 quarters
13F position evolutionNo 13F history in
institutional_holders for GILD-US.